VarmX is developing a bypass agent to restore coagulation for patients facing life-threatening bleeding or...
September 2025
NEW YORK, Sept. 16, 2025 /PRNewswire/ — Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company, today...
Groundbreaking study demonstrates that targeted oligodendrocyte gene therapy leads to decreased N-acetylaspartate (NAA) levels and...
– Current CEO and Co-founder Nancy Briefs Transitions to Executive Chair of the Board –...
COYA 303 is an investigational proprietary combination of LD-IL-2 and GLP-1RA for subcutaneous administration, under...
Specialized AI agents automate research workflows and accelerate drug discovery and development with transparent, evidence-backed...
This tablet press will provide the facility’s Formulation Development Team with an important tool for...
CAMBRIDGE, Mass., Sept. 16, 2025 /PRNewswire/ — Flagship Pioneering, a scientific innovation engine for platforms...
This tablet press will provide the facility’s Formulation Development Team with an important tool for...
– Versant Ventures and Qiming Venture Partners USA co-led financing with participation from founding investor...